A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer

Katsumasa Kuroi, Kojiro Shimozuma, Yasuo Ohashi, Ayano Takeuchi, Toshihiko Aranishi, Satoshi Morita, Shozo Ohsumi, Toru Watanabe, Stacey Bain, Frederick H. Hausheer

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: Since there is now growing interest in the incorporation of patient-reported outcome measures in cancer clinical trials, a patient-based questionnaire, the Patient Neurotoxicity Questionnaire (PNQ) was developed to quantify the symptoms and severity of chemotherapy-induced peripheral neuropathy (CIPN). The aim of this study was to evaluate the physicians' perspectives regarding the utility and diagnostic value of PNQ. Methods: A questionnaire was sent to 61 physicians who participated in a Phase III randomized trial of adjuvant chemotherapy in breast cancer (AC followed by taxane versus taxane alone) that used the PNQ to assess CIPN. Results: Forty-seven out of 61 physicians (77%) responded. The majority considered neurosensory symptoms the diagnostic hallmark for CIPN and most regarded interference with activities of daily living (ADLs) as definite justification for treatment modifications. For neurosensory disturbance, the majority of physicians indicated that Grade D severity (moderate to severe symptoms interfering with ADLs) should result in treatment postponement and Grade E severity (severe symptoms preventing most ADLs) should result in treatment discontinuation. Similarly, for neuromotor disturbance, over half of the physicians replied that Grade C (moderate symptoms not interfering with ADLs), D and E severity should result in dose reduction, treatment postponement and treatment discontinuation, respectively. Eighty-four percentage of the physicians reported that the use of the PNQ was helpful in the diagnosis and assessment of patients at risk of CIPN. Conclusions: The PNQ appears tobe a useful instrument for the diagnosis and grading of CIPN, as well as for clinical decision-making regarding treatment modifications secondary to CIPN.

Original languageEnglish
Pages (from-to)748-754
Number of pages7
JournalJapanese Journal of Clinical Oncology
Volume38
Issue number11
DOIs
Publication statusPublished - 2008
Externally publishedYes

Fingerprint

Peripheral Nervous System Diseases
Breast Neoplasms
Physicians
Drug Therapy
Activities of Daily Living
Therapeutics
Adjuvant Chemotherapy
Surveys and Questionnaires
Clinical Trials
Neoplasms

Keywords

  • Breast cancer
  • Chemotherapy
  • Neuropathy
  • Patient-reported outcome
  • Questionnaire

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer. / Kuroi, Katsumasa; Shimozuma, Kojiro; Ohashi, Yasuo; Takeuchi, Ayano; Aranishi, Toshihiko; Morita, Satoshi; Ohsumi, Shozo; Watanabe, Toru; Bain, Stacey; Hausheer, Frederick H.

In: Japanese Journal of Clinical Oncology, Vol. 38, No. 11, 2008, p. 748-754.

Research output: Contribution to journalArticle

Kuroi, Katsumasa ; Shimozuma, Kojiro ; Ohashi, Yasuo ; Takeuchi, Ayano ; Aranishi, Toshihiko ; Morita, Satoshi ; Ohsumi, Shozo ; Watanabe, Toru ; Bain, Stacey ; Hausheer, Frederick H. / A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer. In: Japanese Journal of Clinical Oncology. 2008 ; Vol. 38, No. 11. pp. 748-754.
@article{f5296945be424732be6cf1e5744682c2,
title = "A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer",
abstract = "Objective: Since there is now growing interest in the incorporation of patient-reported outcome measures in cancer clinical trials, a patient-based questionnaire, the Patient Neurotoxicity Questionnaire (PNQ) was developed to quantify the symptoms and severity of chemotherapy-induced peripheral neuropathy (CIPN). The aim of this study was to evaluate the physicians' perspectives regarding the utility and diagnostic value of PNQ. Methods: A questionnaire was sent to 61 physicians who participated in a Phase III randomized trial of adjuvant chemotherapy in breast cancer (AC followed by taxane versus taxane alone) that used the PNQ to assess CIPN. Results: Forty-seven out of 61 physicians (77{\%}) responded. The majority considered neurosensory symptoms the diagnostic hallmark for CIPN and most regarded interference with activities of daily living (ADLs) as definite justification for treatment modifications. For neurosensory disturbance, the majority of physicians indicated that Grade D severity (moderate to severe symptoms interfering with ADLs) should result in treatment postponement and Grade E severity (severe symptoms preventing most ADLs) should result in treatment discontinuation. Similarly, for neuromotor disturbance, over half of the physicians replied that Grade C (moderate symptoms not interfering with ADLs), D and E severity should result in dose reduction, treatment postponement and treatment discontinuation, respectively. Eighty-four percentage of the physicians reported that the use of the PNQ was helpful in the diagnosis and assessment of patients at risk of CIPN. Conclusions: The PNQ appears tobe a useful instrument for the diagnosis and grading of CIPN, as well as for clinical decision-making regarding treatment modifications secondary to CIPN.",
keywords = "Breast cancer, Chemotherapy, Neuropathy, Patient-reported outcome, Questionnaire",
author = "Katsumasa Kuroi and Kojiro Shimozuma and Yasuo Ohashi and Ayano Takeuchi and Toshihiko Aranishi and Satoshi Morita and Shozo Ohsumi and Toru Watanabe and Stacey Bain and Hausheer, {Frederick H.}",
year = "2008",
doi = "10.1093/jjco/hyn100",
language = "English",
volume = "38",
pages = "748--754",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer

AU - Kuroi, Katsumasa

AU - Shimozuma, Kojiro

AU - Ohashi, Yasuo

AU - Takeuchi, Ayano

AU - Aranishi, Toshihiko

AU - Morita, Satoshi

AU - Ohsumi, Shozo

AU - Watanabe, Toru

AU - Bain, Stacey

AU - Hausheer, Frederick H.

PY - 2008

Y1 - 2008

N2 - Objective: Since there is now growing interest in the incorporation of patient-reported outcome measures in cancer clinical trials, a patient-based questionnaire, the Patient Neurotoxicity Questionnaire (PNQ) was developed to quantify the symptoms and severity of chemotherapy-induced peripheral neuropathy (CIPN). The aim of this study was to evaluate the physicians' perspectives regarding the utility and diagnostic value of PNQ. Methods: A questionnaire was sent to 61 physicians who participated in a Phase III randomized trial of adjuvant chemotherapy in breast cancer (AC followed by taxane versus taxane alone) that used the PNQ to assess CIPN. Results: Forty-seven out of 61 physicians (77%) responded. The majority considered neurosensory symptoms the diagnostic hallmark for CIPN and most regarded interference with activities of daily living (ADLs) as definite justification for treatment modifications. For neurosensory disturbance, the majority of physicians indicated that Grade D severity (moderate to severe symptoms interfering with ADLs) should result in treatment postponement and Grade E severity (severe symptoms preventing most ADLs) should result in treatment discontinuation. Similarly, for neuromotor disturbance, over half of the physicians replied that Grade C (moderate symptoms not interfering with ADLs), D and E severity should result in dose reduction, treatment postponement and treatment discontinuation, respectively. Eighty-four percentage of the physicians reported that the use of the PNQ was helpful in the diagnosis and assessment of patients at risk of CIPN. Conclusions: The PNQ appears tobe a useful instrument for the diagnosis and grading of CIPN, as well as for clinical decision-making regarding treatment modifications secondary to CIPN.

AB - Objective: Since there is now growing interest in the incorporation of patient-reported outcome measures in cancer clinical trials, a patient-based questionnaire, the Patient Neurotoxicity Questionnaire (PNQ) was developed to quantify the symptoms and severity of chemotherapy-induced peripheral neuropathy (CIPN). The aim of this study was to evaluate the physicians' perspectives regarding the utility and diagnostic value of PNQ. Methods: A questionnaire was sent to 61 physicians who participated in a Phase III randomized trial of adjuvant chemotherapy in breast cancer (AC followed by taxane versus taxane alone) that used the PNQ to assess CIPN. Results: Forty-seven out of 61 physicians (77%) responded. The majority considered neurosensory symptoms the diagnostic hallmark for CIPN and most regarded interference with activities of daily living (ADLs) as definite justification for treatment modifications. For neurosensory disturbance, the majority of physicians indicated that Grade D severity (moderate to severe symptoms interfering with ADLs) should result in treatment postponement and Grade E severity (severe symptoms preventing most ADLs) should result in treatment discontinuation. Similarly, for neuromotor disturbance, over half of the physicians replied that Grade C (moderate symptoms not interfering with ADLs), D and E severity should result in dose reduction, treatment postponement and treatment discontinuation, respectively. Eighty-four percentage of the physicians reported that the use of the PNQ was helpful in the diagnosis and assessment of patients at risk of CIPN. Conclusions: The PNQ appears tobe a useful instrument for the diagnosis and grading of CIPN, as well as for clinical decision-making regarding treatment modifications secondary to CIPN.

KW - Breast cancer

KW - Chemotherapy

KW - Neuropathy

KW - Patient-reported outcome

KW - Questionnaire

UR - http://www.scopus.com/inward/record.url?scp=55149102843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55149102843&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyn100

DO - 10.1093/jjco/hyn100

M3 - Article

C2 - 18845520

AN - SCOPUS:55149102843

VL - 38

SP - 748

EP - 754

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 11

ER -